Cellular Origins and Fresenius Kabi completed the first phase of their collaboration to scale cell and gene therapy manufacturing by integrating Fresenius Kabi’s Cue R cell processing system into Cellular Origins’ Constellation R robotic manufacturing platform. The partners reported successful digital and physical integration and human T‑cell studies that validate automated execution of complex workflows. The milestone aims to reduce manual interventions, lower variability and cut manufacturing cost per batch—critical bottlenecks for commercializing autologous and allogeneic cell therapies. Companies and CDMOs will watch subsequent scale‑up and regulatory validation steps.